long intergenic non-protein coding RNA 339 (LINC00339)

Long intergenic non-protein coding RNA 339 (LINC00339) is a long noncoding RNA located on human chromosome 1p36 that functions as a multifunctional regulatory molecule, primarily through post-transcriptional mechanisms such as acting as a competing endogenous RNA (ceRNA) to sequester microRNAs[1][2][4]. It is implicated in various diseases, most notably as an oncogenic lncRNA in diverse cancers where it promotes cell proliferation, migration, invasion, and resistance to apoptosis by releasing oncogene effectors[1][2]. In nonmalignant conditions such as osteoporosis, LINC00339 acts as a negative regulator of osteoblast differentiation, functioning through a cytoplasmic complex with PARP1 that influences the stability of CDC42 protein[4]. The molecule has also been reported in other diseases including endometriosis and inflammatory states, and may be considered a diagnostic or prognostic biomarker in some contexts[1][4]. While it is not a receptor, enzyme, or classical drug target, its disease relevance and pivotal regulatory functions make it a candidate for therapeutic targeting and biomarker development, though the clinical translation of lncRNA-targeted therapies is still in early stages[1][4][5].

Other names

HSPC157NCRNA00339

MicroRNA sponging (e.g., sequestering miR-145, miR‑377‑3p, miR‑497‑5p, miR‑152, miR‑539‑5p, miR‑378a-3p); Regulation of oncogenes (e.g., HOXC6, FOXM1, IGF1R, DCP1A, ROCK1, TWIST1); Negative regulation of CDC42 via interaction with PARP1